Skip to main content
Premium Trial:

Request an Annual Quote

OpGen to Meet With Nasdaq Panel to Stave Off Delisting

NEW YORK (GenomeWeb) – OpGen will meet with a Nasdaq panel in early 2018 to stave off being delisted from the exchange, the company said in a regulatory document on Tuesday.

In a Form 8-K filing with the US Securities and Exchange Commission, OpGen said that it received written notice on Dec. 21 from Nasdaq informing the company that the exchange would be delisting its stock on Jan. 2, 2018 if it did not request a hearing with a Nasdaq Hearing Panel in relation to the firm's failure to meet certain listing requirements.

In June, OpGen was warned by Nasdaq that it had failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days. The exchange gave the company until Dec. 18 to regain compliance.

In May, Nasdaq also warned the firm that fell short of a listing requirement calling for at least $2.5 million in stockholders' equity. In its letter last week, Nasdaq told OpGen that it failed to comply with either listing requirements and was thus ineligible for an additional 180-day extension to meet the minimum bid price requirement, OpGen said.

OpGen requested on Dec. 21 to meet with the Nasdaq panel, staying any suspension or delisting action until the hearing process is concluded and any extension may be granted. An oral hearing is scheduled for Feb. 8, OpGen said in its SEC document.

It added that it has filed a proxy statement for a special meeting of shareholders on Jan. 17, to seek approval for a reverse stock split to meet Nasdaq's minimum bid price.

In early morning trading today, OpGen's shares were down 4 percent at $.1511. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.